Searched for
DRL PAT
Stocks in news: Eternal, Tata Motors, Restaurant Brands Asia, AU Small Finance Bank, RBL BankIndian markets saw a decline on Tuesday due to widespread selling and weak global sentiment. Analysts are watching key sectors like banking...- Stocks in news: Infosys, Dr Reddy's, Paytm, IRFC, United BreweriesMarkets remained range-bound on Tuesday as investors awaited key earnings reports. Several companies, including Infosys, Tata Consumer, and...
- Bain dials Dr Reddy's Laboratories to team up for joint Cipla bidPrivate equity firm Bain Capital has approached Indian pharmaceutical company Dr Reddy's Laboratories (DRL) to explore a joint bid for the ...
- US generic business won't show any significant growth for pharma companies for next 1-2 years: Aditya KhemkaOn one hand, you have the US generic business where the raw material cost decline will obviously help the margins. But you would also have ...
- Dr Reddy's Q3 Results: PAT jumps 77% YoY to Rs 1,247 crore, beats estimatesAn ET Now poll had showed that analysts were expecting PAT at Rs 910 crore and revenue at Rs 5,830 crore.
- Earnings Tracker: TCS to kickstart Q3 result season on January 9"The third interim dividend, if declared, shall be paid to the equity shareholders of the company whose names appear on the register of mem...
- DRL Q3 Results: Drugmaker posts 25 times rise in PAT at Rs 709 cr, in line with estimatesThe revenue from operations came in at Rs 5,103 crore, up 8.3 per cent against Rs 4,711 crore in the corresponding quarter last year.
- DRL Q3 Results Preview: Profit may grow 25% YoY; margin likely to fallEdelweiss sess profit rising 26.5 per cent YoY to Rs 780 crore. It sees sales rising 12.2 per cent YoY to Rs 5,531 crore. The brokerage see...
- Dr Reddy’s Q2 results: Consolidated PAT rises 30% YoY, beats estimateThe drugmaker reported an 18 per cent on-year rise in consolidated revenues to Rs. 5,763 crore for the reported quarter, which also beat St...
- Analyst Calls: DRL, BoB, Hindalco, FinolexAnand Rathi has initiated coverage on Dixon Technologies (India) with a target price of Rs 5,822.
- Reduce Dr. Reddy's Laboratories, target Rs 2,759: Elara CapitalDr. Reddy's Laboratories is a largecap company, operating in pharmaceuticals and health care sector.
- Siddhartha Khemka of MOFSL is bullish on these 3 corporate banksMetal packs have been the single biggest drivers of Nifty earnings for the quarter, says Khemka
- IIFL’s Abhimanyu Sofat is bullish on this smallcap, here's why“We will continue to be overweight on IT sector going forward”
- Expect record EBITDA from JSW Steel: Parag Thakkar, Head-Institutional Sales, HDFC SecuritiesThings are great for companies like Asian Paints, UltraTech but how much value is on the table that is to be seen.
- Sensex rallies, ends 460 points higher; Nifty50 reclaims 7,850; Bajaj Auto gains 4%The domestic equity market made a strong comeback on Monday following strong global and domestic cues after a rather disappointing week.
- Look who moved my market on ThursdaySensex plunged over 800 points on Thursday tracking weak cues from other Asian and European markets and weak earnings by leading index cons...
- Dr Reddy's Lab Q2 net rises 26% to Rs 722 croreSaumen Chakraborty, chief financial officer of Dr Reddy’s said, despite headwinds from a few segments, the company did well during the quar...
- Sensex, Nifty turn negative after hitting record highs; top 20 trading ideasThe Sensex slipped over 250 points in trade on Friday, after hitting fresh record high of 26300.17, led by losses in ICICI Bank, Wipro & RI...
- Markets to reward performers, Eicher Motors top pick: Sonam UdasiFor Sun Pharma and DRL, basically the premium that the market was giving them should sustain, says Sonam Udasi of IDBI Capital.
- Indian pharma cos market revenue share up at 32 pcForex gains also contributed significantly to the bottom-line of many pharma companies for the quarter Q2 FY13.
Load More
